Results 101 to 110 of about 10,116 (213)

“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1479-1481, November 2026.
ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan, Alyssa Kobayashi, Zhina Sadeghi   +2 more
wiley   +1 more source

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1500-1506, November 2026.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

The Isolation of Type B Botulinum Toxin [PDF]

Journal of Bacteriology, 1947
C, Lamanna, H N, Glassman
openaire   +2 more sources

Urodynamic Voiding Patterns in Multiple Sclerosis

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1569-1577, November 2026.
ABSTRACT Aims This study aimed to describe urodynamic voiding patterns in patients with MS (PwMS) using standardized assessments, and to compare the performance of the available nomograms and indices for obstruction and bladder contractility. Methods PwMS and lower urinary tract symptoms underwent cystometry and pressure flow studies.
Camille Chesnel, Nicolas Turmel, Maelys Teng, Emilie Blouet, Gérard Amarenco, Claire Hentzen   +5 more
wiley   +1 more source

Health‐related quality of life and patient‐reported outcome measures in economic evaluation of urological technologies: challenges and opportunities

BJU International, Volume 138, Issue 5, Page 750-758, November 2026.
Objective To examine the role of health‐related quality of life (HRQoL) assessments and patient‐reported outcome measures (PROMs) in the economic evaluation of urological interventions, highlighting methodological challenges, and identifying areas for future development.
Mohammed El Bahnasawi, Charlotte Moss, Netty Kinsella, Kathie Alexina Wong, Mieke Van Hemelrijck   +4 more
wiley   +1 more source

Botulinum Toxin Type A [PDF]

, 2020
openaire   +1 more source

Evaluation of a Multipolar MEMS Based Low‐Power Radiofrequency Device for Pain‐Free Facial Rejuvenation: A Prospective Clinical Study

Journal of Cosmetic Dermatology, Volume 25, Issue 11, November 2026.
ABSTRACT Background Noninvasive radiofrequency (RF) therapy has emerged as a prominent approach for facial rejuvenation due to its ability to stimulate collagen remodeling without epidermal ablation. However, conventional RF systems often rely on high thermal output, posing risks of heat‐induced dermal damage. Objective This study aimed to evaluate the
Rongwei Mao, Shengshuo Yan, Aditi A. Sharma, Tony Shum, Yang Zhang   +4 more
wiley   +1 more source

Botulinum Toxins Type A (Bont-A) in the Management of Lower Limb Spasticity in Children: A Systematic Literature Review and Bayesian Network Meta-analysis. [PDF]

J Child Neurol, 2019
Guyot P, Kalyvas C, Mamane C, Danchenko N.   +3 more
europepmc   +1 more source

Recovery from Abobotulinum Toxin A-Induced Paralysis Following Ozone Injection in a Split-Body Rabbit Model. [PDF]

Toxins (Basel)
Tuna A, Botsalı A, Şen M, Aksoy OA, Öztürk ÖB, Çalışkan E.   +5 more
europepmc   +1 more source

Temporal Scientific Signals Associated with Regulatory Milestones in Anatomically Targeted Therapeutics: Evidence from Botulinum Toxin Research. [PDF]

Toxins (Basel)
Lin Y, Choi Y, Liu X, Jeon HD, Park HJ.
europepmc   +1 more source